Hobart Private Capital, LLC Amgen Inc Transaction History

Hobart Private Capital, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Mar 11, 2024	SELL	$216.38 - $257.67 $1,081 - $1,288	-5 Reduced 0.15%	3,257 $749 Million
Q3 2020 Mar 11, 2024	SELL	$234.65 - $260.95 $103,480 - $115,078	-441 Reduced 11.91%	3,262 $829 Million
Q2 2020 Mar 11, 2024	SELL	$197.81 - $242.74 $15,429 - $18,933	-78 Reduced 2.06%	3,703 $873 Million
Q1 2020 Mar 11, 2024	SELL	$182.24 - $241.7 $49,751 - $65,984	-273 Reduced 6.73%	3,781 $766 Million
Q4 2019 Mar 11, 2024	BUY	$189.21 - $243.2 $767,057 - $985,932	4,054 New	4,054 $977 Million
Q3 2019 Mar 11, 2024	BUY	$174.11 - $208.62 $15,147 - $18,149	87 Added 5.59%	1,643 $318 Million
Q2 2019 Mar 11, 2024	BUY	$166.7 - $195.41 $39,507 - $46,312	237 Added 17.97%	1,556 $287 Million
Q1 2019 Mar 11, 2024	SELL	$180.87 - $203.88 $30,024 - $33,844	-166 Reduced 11.18%	1,319 $251 Million
Q4 2018 Mar 11, 2024	BUY	$178.4 - $208.25 $38,891 - $45,398	218 Added 17.21%	1,485 $289 Million
Q3 2018 Mar 11, 2024	BUY	$185.29 - $208.89 $234,762 - $264,663	1,267 New	1,267 $263 Million

3,122

409M

7.56M

7.2M

Ticker AMGN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 534,931,008
Market Cap $149B
Description
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...

Get notified when there are updates to the investment portfolio of Hobart Private Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Hobart Private Capital, LLC with notifications on news.